SAILIFE Sai Life Q3 FY26 results (Oct–Dec 2025) and concall
Sai Life Sciences Limited reported a robust Q3 FY26, with revenue growing 27% YoY to INR 556 crores and EBITDA surging 54% YoY to INR 191 crores, achieving a 34% margin. For the nine-month period, revenue increased 43% YoY to INR 1,590 crores, and EBITDA grew 79% YoY to INR 472 crores, reaching a 30% margin. The company is ahead of schedule on its 28-30% EBITDA margin target and is progressing well with significant capacity expansions across its R&D and manufacturing facilities, driven by strong demand and strategic customer partnerships.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 26.4%, net profit up 85.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 396 | 440 | 580 | 496 | 537 +36% | 556 +26% |
| EBITDA | 102 | 120 | 158 | 121 | 146 +43% | 188 +57% |
| Net profit | 42 | 54 | 88 | 60 | 84 +100% | 100 +85% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
